PTX 2.56% 3.8¢ prescient therapeutics limited

Ann: Canadian Patent Granted for PTX-200, page-3

  1. 244 Posts.
    lightbulb Created with Sketch. 63
    It is good news.... but not one of the big trial results or interim data we are all actually waiting for. A new patent for the target market (PTX-200 used in combination with Taxanes and Platinum-based chemotherapy) is progress. I find the wording interesting "for patients with cancer" as this does not limit treatment indications to Breast, Ovarian and AML patients.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
3.8¢
Change
-0.001(2.56%)
Mkt cap ! $30.60M
Open High Low Value Volume
3.9¢ 3.9¢ 3.8¢ $47.91K 1.256M

Buyers (Bids)

No. Vol. Price($)
11 881755 3.8¢
 

Sellers (Offers)

Price($) Vol. No.
3.9¢ 150000 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.